| Peak Healthcare At The Pines | |
| 610 Dutchman's Lane, Easton, Maryland 21601 | |
| (410) 822-4000 | |
| Name | Peak Healthcare At The Pines |
|---|---|
| Location | 610 Dutchman's Lane, Easton, Maryland |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 170 |
| Occupancy Rate | 48.29% |
| Medicare ID (CCN) | 215010 |
| Legal Business Name | Easton Md Opco Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1205461001 |
| Organization Name | EASTON MD OPCO LLC |
| Address | 610 Dutchmans Ln, Easton, MD 21601 |
| Phone Number | 410-822-4000 |
News Archive
Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.
Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
A new study has identified discrimination, alcohol and tobacco as significant predictors of minority Americans' experiencing panic attacks — fearful spells with psychological symptoms that last a few minutes and are often debilitating and disruptive.
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).
› Verified 2 days ago
| NPI Number | 1427091602 |
| Organization Name | MERIDIAN HEALTH, INC. |
| Doing Business As | THE PINES |
| Address | 610 Dutchmans Ln, Easton, MD 21601 |
| Phone Number | 410-822-4000 |
News Archive
Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.
Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
A new study has identified discrimination, alcohol and tobacco as significant predictors of minority Americans' experiencing panic attacks — fearful spells with psychological symptoms that last a few minutes and are often debilitating and disruptive.
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).
› Verified 2 days ago
| NPI Number | 1639894934 |
| Organization Name | PINES NURSING AND REHAB, LLC |
| Address | 610 Dutchmans Ln, Easton, MD 21601 |
| Phone Number | 410-822-4000 |
News Archive
Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.
Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
A new study has identified discrimination, alcohol and tobacco as significant predictors of minority Americans' experiencing panic attacks — fearful spells with psychological symptoms that last a few minutes and are often debilitating and disruptive.
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).
› Verified 2 days ago
| NPI Number | 1811179385 |
| Organization Name | 610 DUTCHMANS LANE OPERATIONS LLC |
| Doing Business As | THE PINES |
| Address | 610 Dutchmans Ln, Easton, MD 21601 |
| Phone Number | 410-822-4000 |
News Archive
Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.
Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
A new study has identified discrimination, alcohol and tobacco as significant predictors of minority Americans' experiencing panic attacks — fearful spells with psychological symptoms that last a few minutes and are often debilitating and disruptive.
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.
Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
A new study has identified discrimination, alcohol and tobacco as significant predictors of minority Americans' experiencing panic attacks — fearful spells with psychological symptoms that last a few minutes and are often debilitating and disruptive.
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 31.27 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 14.83 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 70.73 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.88 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.51 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.67 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.71 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.03 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 84.04 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.04 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 43.47 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.24 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 51.21 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.11 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 9.88 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.59 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 69.25 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 53.74 | 82.93 |
News Archive
Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.
Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
A new study has identified discrimination, alcohol and tobacco as significant predictors of minority Americans' experiencing panic attacks — fearful spells with psychological symptoms that last a few minutes and are often debilitating and disruptive.
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).
› Verified 2 days ago
Peak Healthcare At The Pines Location: 610 Dutchman's Lane, Easton, Maryland 21601 Phone: (410) 822-4000 | |